Claritev Corporation
NYSE:CTEVMedical - Healthcare Information Services
+$0.42 today
- Market cap
- $380.77M
- Beta
- 0.77
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$17.16
Volume 0.31M
Average 0.14M
CTEV Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Claritev CorporationNYSE: CTEV
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 7.8% from a year ago
Cash & equivalents stood at $21.33M at the end of Q1 FY2026, down 7.8% from a year earlier and up 26.8% from the prior quarter. Over 3 fiscal years it compounded at -63.1% a year.
Context
- Cash & equivalents amounted to 0.4% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -7.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 16.81M USD
- Year-over-year change
- -0.2%
- 4-year CAGR
- -45.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.81M | -0.2% |
| FY2024 | 2024-12-31 | 16.85M | -76.5% |
| FY2023 | 2023-12-31 | 71.55M | -78.6% |
| FY2022 | 2022-12-31 | 334.05M | +80.2% |
| FY2021 | 2021-12-31 | 185.33M | — |
Cash & Equivalents vs competitors
How CTEV compares with its peers on the latest reported figures
- CTEV's Mar 2026 cash & equivalents of $21.33M is the lowest of the 11 companies compared; the peer median is $200.86M.
- Its year-over-year change of -7.8% is the 7th highest of 11, against a peer median of -0.4%.
- Cash & equivalents amounts to 0.4% of total assets for CTEV, versus a peer median of 20.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $394.3M | +170.2% | +45.8% | 52.5% | |
| Mar 2026 | $341.88M | -21.6% | +34.1% | 18.4% | |
| Sep 2026 | $328.89M | +1276.0% | +32.5% | 59.8% | |
| Mar 2026 | $236.81M | -1.0% | -19.9% | 6.6% | |
| Mar 2026 | $235.71M | -21.7% | -29.8% | 11.7% | |
| Mar 2026 | $166.01M | -32.7% | -6.9% | 8.8% | |
| Jun 2026 | $110.55M | +735.2% | +49.3% | 9.1% | |
| Mar 2026 | $83.8M | -12.8% | -25.9% | 22.4% | |
| Mar 2026 | $56.37M | +12.0% | -4.1% | 49.3% | |
| Mar 2026 | $34.48M | +0.2% | +110.2% | 49.2% | |
CTEVClaritev Corporation | Mar 2026 | $21.33M | -7.8% | -63.1% | 0.4% |
| Peer median (excluding CTEV) | $200.86M | -0.4% | +14.2% | 20.4% | |
Competitors are the stored peer set for CTEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 185.33M | 334.05M | 71.55M | 16.85M | 16.81M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 99.91M | 78.91M | 84.76M | 111.61M | 138.18M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 4.05M | 10.19M | 12.5M | 19.82M | 25.86M |
| Total Current Assets | 319.26M | 446.74M | 193.59M | 175.52M | 224.37M |
| Property, Plant & Equipment (Net) | 243.34M | 257.07M | 287.11M | 308.75M | 340.29M |
| Goodwill | 4.36B | 3.71B | 3.83B | 2.4B | 2.41B |
| Intangible Assets | 3.29B | 2.94B | 2.63B | 2.23B | 1.88B |
| Long-term Investments | 0 | 0 | 0 | 15M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 9.7M | 21.9M | 21.78M | 22.1M | 33.34M |
| Total Non-current Assets | 7.9B | 6.92B | 6.77B | 4.98B | 4.66B |
| Total Assets | 8.22B | 7.37B | 6.96B | 5.15B | 4.89B |
| Account Payables | 13.01M | 13.3M | 19.59M | 86.33M | 60.46M |
| Short-term Debt | 13.25M | 13.25M | 13.25M | 13.25M | 19.4M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 25.42M | 34.57M | 44.72M | 33.69M | 181.5M |
| Total Current Liabilities | 141.91M | 175.84M | 166.74M | 213.79M | 261.36M |
| Long-term Debt | 4.88B | 4.74B | 4.53B | 4.51B | 4.6B |
| Deferred Tax Liabilities | 753.83M | 639.5M | 521.71M | 325.83M | 197.6M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 74.14M | 2.47M | 17.26M | 3.6M | (16.24M) |
| Total Non-current Liabilities | 5.73B | 5.4B | 5.09B | 4.85B | 4.79B |
| Total Liabilities | 5.88B | 5.58B | 5.26B | 5.07B | 5.06B |
| Common Stock | 67K | 67K | 2K | 2K | 2K |
| Retained Earnings | 225.11M | (347.8M) | (499.31M) | (2.15B) | (2.43B) |
| Accumulated OCI | 0 | 0 | (11.78M) | (5.06M) | (4.17M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 6.73M |
| Total Equity | 2.34B | 1.79B | 1.71B | 84.02M | (167.18M) |
| Total Debt | 4.93B | 4.78B | 4.57B | 4.54B | 4.63B |
| Net Debt | 4.74B | 4.45B | 4.5B | 4.52B | 4.62B |
Claritev Corporation
NYSE:CTEV
Intrinsic Alpha fair value
Locked
Current Price
$22.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.